Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD). [More]
Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Scientific research into CGM-like sensors goes back more than 40 years. I was working with the first company to begin commercial development, MiniMed, back in 1992 when the science was really beginning to percolate. In 1999 the FDA approved the first CGM device for use in the United States. [More]

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda Pharmaceuticals Company Limited will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC. [More]
Expert highlights the importance of gender-specific approach for treating diabetes mellitus

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

The international guidelines on the drug-based therapy of diabetes mellitus specify which factors need to be taken into account during treatment. [More]
Investigators urge drug regulators to provide clear evidence on statins’ side effects

Investigators urge drug regulators to provide clear evidence on statins’ side effects

At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them. [More]
Viewpoints: Obama's budget punts on entitlements; Medicaid debate rankles states

Viewpoints: Obama's budget punts on entitlements; Medicaid debate rankles states

There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year -; 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4). [More]
Study: Residents of socioeconomically deprived regions suffer from diabetes, obesity

Study: Residents of socioeconomically deprived regions suffer from diabetes, obesity

Living in a socioeconomically deprived region is a risk factor for being affected by diabetes mellitus and obesity. This holds true regardless of the individual social status of the inhabitants. [More]

Residents of socioeconomically deprived regions suffer from diabetes and obesity

Living in a socioeconomically deprived region is a risk factor for being affected by diabetes mellitus and obesity. This holds true regardless of the individual social status of the inhabitants. This is the conclusion reached by scientists from the Institute of Health Economics and Health Care Management at the Helmholtz Zentrum München and the Department of Epidemiology and Health Monitoring at the Robert Koch Institute in Berlin. [More]

Difference in interarm blood pressure linked to greater risk of future cardiovascular events

​As heart disease continues to be one of the leading causes of death in the United States, practitioners and patients alike are looking for ways to cut risk factors and identify new clues to assist with early detection. [More]
Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

In preparation for the new ACO environment, leaders recognized the contribution palliative care can make to health care "value," especially in the care of our sickest (and most expensive) patients ... [More]
FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA. [More]
Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. [More]
Bosch Healthcare receives NCQA's Disease Management certification for HMPs

Bosch Healthcare receives NCQA's Disease Management certification for HMPs

Robert Bosch Healthcare Systems, Inc., the market leader in evidence-based telehealth solutions, today announced the that it has received certification for program design in Disease Management for 16 Health Management Programs (HMPs) that it submitted to the National Committee for Quality Assurance. [More]
Women visit recommended obstetricians shortly after giving birth, but slightly fewer than half

Women visit recommended obstetricians shortly after giving birth, but slightly fewer than half

Medical associations widely recommend that women visit their obstetricians and primary care doctors shortly after giving birth, but slightly fewer than half make or keep those postpartum appointments, according to a study by Johns Hopkins researchers. [More]

Women must visit obstetricians, primary care doctors after childbirth

Medical associations widely recommend that women visit their obstetricians and primary care doctors shortly after giving birth, but slightly fewer than half make or keep those postpartum appointments, according to a study by Johns Hopkins researchers. [More]

Women with schizophrenia twice as likely to experience pre-term birth and pregnancy complications

Women with schizophrenia are nearly twice as likely to experience pre-eclampsia, pre-term birth and other serious pregnancy and delivery complications as women without the condition, a landmark study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital has found. [More]
Blood pressure lowering linked with reduced risk for cognitive decline in patients with T2DM

Blood pressure lowering linked with reduced risk for cognitive decline in patients with T2DM

Intensive blood pressure and cholesterol lowering was not associated with reduced risk for diabetes-related cognitive decline in older patients with long-standing type 2 diabetes mellitus, according to a study by Jeff D. Williamson, M.D., M.H.S., of the Wake Forest School of Medicine, Winston-Salem, N.C., and colleagues. [More]
Scientists provide new insights into molecular regulation of stem cell differentiation

Scientists provide new insights into molecular regulation of stem cell differentiation

The findings of the scientists of the Institute of Diabetes and Regeneration Research (IDR) at Helmholtz Zentrum München (HMGU) provide new insights into the molecular regulation of stem cell differentiation. [More]
Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014. [More]